242 related articles for article (PubMed ID: 35299965)
41. Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria.
Guo M; Chen ZJ; Macklon NS; Shi YH; Westerveld HE; Eijkemans MJ; Fauser BC; Goverde AJ
Reprod Biomed Online; 2010 Oct; 21(4):572-80. PubMed ID: 20800551
[TBL] [Abstract][Full Text] [Related]
42. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome.
Krentowska A; Kowalska I
Diabetes Metab Res Rev; 2022 Jan; 38(1):e3464. PubMed ID: 33988288
[TBL] [Abstract][Full Text] [Related]
43. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.
Goverde AJ; van Koert AJ; Eijkemans MJ; Knauff EA; Westerveld HE; Fauser BC; Broekmans FJ
Hum Reprod; 2009 Mar; 24(3):710-7. PubMed ID: 19095675
[TBL] [Abstract][Full Text] [Related]
44. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population.
Zhang HY; Zhu FF; Xiong J; Shi XB; Fu SX
BJOG; 2009 Nov; 116(12):1633-9. PubMed ID: 19781047
[TBL] [Abstract][Full Text] [Related]
45. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
Bell RJ; Islam RM; Skiba MA; Herbert D; Martinez Garcia A; Davis SR
Hum Reprod; 2021 Dec; 37(1):109-118. PubMed ID: 34741176
[TBL] [Abstract][Full Text] [Related]
46. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis.
Lizneva D; Kirubakaran R; Mykhalchenko K; Suturina L; Chernukha G; Diamond MP; Azziz R
Fertil Steril; 2016 Nov; 106(6):1510-1520.e2. PubMed ID: 27530062
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.
Clark NM; Podolski AJ; Brooks ED; Chizen DR; Pierson RA; Lehotay DC; Lujan ME
Reprod Sci; 2014 Aug; 21(8):1034-1043. PubMed ID: 24520081
[TBL] [Abstract][Full Text] [Related]
48. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
Ezeh U; Ezeh C; Pisarska MD; Azziz R
Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
[TBL] [Abstract][Full Text] [Related]
49. Endocrinological and Metabolic Heterogeneity Is Low in Japanese Women With Polycystic Ovary Syndrome.
Baba T; Endo T; Mariya T; Kuno Y; Honnma H; Kanaya M; Saito T
J Obstet Gynaecol Can; 2024 Jan; 46(1):102217. PubMed ID: 37709141
[TBL] [Abstract][Full Text] [Related]
50. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
51. [Diagnostics of polycystic ovary syndrome].
Lazúrová I; Figurová J; Lazúrová Z
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S40-4. PubMed ID: 27124971
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic characteristics and metabolic risk factors of cases with polycystic ovary syndrome during adolescence.
Sıklar Z; Berberoğlu M; Çamtosun E; Kocaay P
J Pediatr Adolesc Gynecol; 2015 Apr; 28(2):78-83. PubMed ID: 25850587
[TBL] [Abstract][Full Text] [Related]
53. Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.
Kim JJ; Hwang KR; Lee D; Kim S; Choi YM
Hum Reprod; 2024 May; 39(5):1072-1077. PubMed ID: 38514450
[TBL] [Abstract][Full Text] [Related]
54. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
[TBL] [Abstract][Full Text] [Related]
55. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.
Sahmay S; Atakul N; Oncul M; Tuten A; Aydogan B; Seyisoglu H
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):157-61. PubMed ID: 23806449
[TBL] [Abstract][Full Text] [Related]
56. Clinical and laboratory features in women with different phenotypes of polycystic ovary syndrome.
Safari A; Mosadeghkhah A; Khameneie MK
Minerva Obstet Gynecol; 2024 Feb; 76(1):27-35. PubMed ID: 35912463
[TBL] [Abstract][Full Text] [Related]
57. Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.
Albu A; Radian S; Fica S; Barbu CG
Endocrine; 2015 Mar; 48(2):696-704. PubMed ID: 25022659
[TBL] [Abstract][Full Text] [Related]
58. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.
Carmina E
Minerva Ginecol; 2004 Feb; 56(1):1-6. PubMed ID: 14973405
[TBL] [Abstract][Full Text] [Related]
59. Association of insulin resistance with polycystic ovary syndrome phenotypes and patients' characteristics: a cross-sectional study in Iran.
Rahmatnezhad L; Moghaddam-Banaem L; Behroozi-Lak T; Shiva A; Rasouli J
Reprod Biol Endocrinol; 2023 Nov; 21(1):113. PubMed ID: 38001527
[TBL] [Abstract][Full Text] [Related]
60. AMH as part of the diagnostic PCOS workup in large epidemiological studies.
Piltonen TT; Komsi E; Morin-Papunen LC; Korhonen E; Franks S; Järvelin MR; Arffman RK; Ollila MM
Eur J Endocrinol; 2023 Jun; 188(6):547-554. PubMed ID: 37294941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
